Fig. 1 · Structure

Documents & Downloads

AEG 3482

Cat. No. A11281 CAS 63735-71-7

JNK inhibitor

AEG 3482 is a small-molecule inhibitor of Jun kinase (JNK)-dependent apoptosis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

AEG 3482 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of AEG 3482 from 3 published references. In vitro models include UM51 cells; utricles from both male and female CBA/J mice. In vivo models include N2 worms.

AEG 3482 In Vitro Studies

UM51 cells treated with the study compound at 10 µM for 72 h showed a highly significant reduction in the ratio of KI67-positive cells to total cell number compared with untreated cells (p < 0.001). Whole organ cultures of utricles from male and female CBA/J mice received compound pretreatment followed by immediate RNA extraction, with vehicle-only utricles as controls. Significant and considerable induction of the measured readout was reported. In MTFs, immunoblot analysis performed 48 hours after compound treatment showed increased protein expression compared with the DMSO control. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced KI67 Positivity in UM51 Cells

Cell-based study · UM51 cells [1]

UM51 cells treated with the study compound at 10 µM for 72 h showed a highly significant reduction in the ratio of KI67-positive cells to total cell number compared with untreated cells (p < 0.001).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ratio of KI67-positive/total cell numberReported result highly significant downregulation of KI67+ UM51 cells (p < 0.001)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
72 h
Co-treatment
Other interventions in this design: bFGF 5 ng/mL. Compound effect isolated by the comparison: with and without JNK inhibition at 72 h.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: AEG 3482

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Cell Culture (S3, S4, S8, S9, S10); 2. Materials and Methods > 2.3. Proliferation Assay (S19, S21); 2. Materials and Methods > 2.7. Flow Cytometry-Based Measurement of Lipid Peroxidation (S40); 3. Results > 3.2. JNK Inhibition Leads to Decreased Proliferation and Loss of Progenitor State (S109, S111, S113)

ratio of KI67-positive/total cell number: ratio of KI67-positive/total cell number; comparator: untreated cells — 2. Materials and Methods > 2.3. Proliferation Assay (S21); 3. Results > 3.2. JNK Inhibition Leads to Decreased Proliferation and Loss of Progenitor State (S113)

Compound Pretreatment in Mouse Utricle Cultures

Cell-based study · utricles from both male and female CBA/J mice (age 4–8 weeks) [2]

Whole organ cultures of utricles from male and female CBA/J mice received compound pretreatment followed by immediate RNA extraction, with vehicle-only utricles as controls. Significant and considerable induction of the measured readout was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hmox1 inductionHmox1 induction roughly 16-fold[2]

Literature-Reported Treatment Conditions

Treatment concentration
25 μM
Exposure duration
6-h pre-treatment followed by immediate RNA extraction
Method
whole organ cultures of utricles from adult mice
Vehicle
0.1% DMSO
Methods and source locations

Compound reported in the paper: AEG 3482

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Organotypic Utricle Explant Culture (S7); Materials and Methods > RT-qPCR Expression (S41); Results > LINCS Hits Induce the Heat Shock Transcriptional Expression Signature in Cultured Mouse Utricles (S142, S144, S147, S152); FIGURE 6 legend (S227)

Hmox1 induction: Hmox1 induction; comparator: control utricles treated only with the 0.1% DMSO vehicle — Results > LINCS Hits Induce the Heat Shock Transcriptional Expression Signature in Cultured Mouse Utricles (S152)

Increased Protein Expression Following Compound Treatment in MTFs

Cell-based study · MTFs [3]

In MTFs, immunoblot analysis performed 48 hours after compound treatment showed increased protein expression compared with the DMSO control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
immunoblot analysis for GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) and GCLM (Glutamate-Cysteine Ligase Modifier Subunit) (subunits of glutamate cysteine ligase, involved in the glutathione synthesis pathway Fig. 5D), and Hmox1Reported result increased protein expression of these Nrf2 targets[3]

Literature-Reported Treatment Conditions

Exposure duration
48 hours after compound treatment
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, route.
Methods and source locations

Compound reported in the paper: AEG 3482

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Transcriptomic analysis reveals that AEG3482 and cardamonin induce Nrf2 target genes (S158, S159); MATERIALS AND METHODS > Immunoblotting (S223); Fig. 5 legend (S280)

immunoblot analysis for GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) and GCLM (Glutamate-Cysteine Ligase Modifier Subunit) (subunits of glutamate cysteine ligase, involved in the glutathione synthesis pathway Fig. 5D), and Hmox1: immunoblot analysis for GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) and GCLM (Glutamate-Cysteine Ligase Modifier Subunit) (subunits of glutamate cysteine ligase, involved in the glutathione synthesis pathway Fig. 5D), and Hmox1; comparator: DMSO — RESULTS > Transcriptomic analysis reveals that AEG3482 and cardamonin induce Nrf2 target genes (S158, S159)

AEG 3482 In Vivo Studies

N2 worms received AEG 3482 at 100 μM on plates seeded with heat-killed bacteria. AEG 3482 enhanced worm survival during PQ challenge compared with PQ alone. [3]

Worm survival during PQ challenge

Animal study · N2 worms [3]

N2 worms received AEG 3482 at 100 μM on plates seeded with heat-killed bacteria. AEG 3482 enhanced survival during PQ challenge compared with PQ alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viabilityReported result AEG 3482 (P < 5 × 10−13, log-rank test) and cardamonin (P < 8 × 10−10, log-rank test), enhanced worm survival in response to PQ challenge[3]

Conditions shared by the study groups

Route
transferred to plates seeded with heat-killed bacteria
Treatment course
until day 5 of adulthood
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AEG 3482 100 μMPQ aloneAEG 3482 (P < 5 × 10−13, log-rank test) and cardamonin (P < 8 × 10−10, log-rank test), enhanced worm survival in response to PQ challenge[3]
AEG 3482 100 μM
Model: N2 worms
Methods and source locations

Compound reported in the paper: AEG 3482

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Cardamonin and AEG 3482 activate SKN-1 signaling in C. elegans to promote oxidative stress resistance (S161); MATERIALS AND METHODS > C. elegans PQ survival assays (S231, S232, S233, S234); Fig. 6 legend (S282)

viability: viability; comparator: PQ alone — RESULTS > Cardamonin and AEG 3482 activate SKN-1 signaling in C. elegans to promote oxidative stress resistance (S161); MATERIALS AND METHODS > C. elegans PQ survival assays (S234)

AEG 3482 100 μM · RESULTS > Cardamonin and AEG 3482 activate SKN-1 signaling in C. elegans to promote oxidative stress resistance (S161); MATERIALS AND METHODS > C. elegans PQ survival assays (S231, S232)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 63735-71-7
Applications JNK inhibitor
Formula C10H8N4O2S2
Molecular Weight 280.33
SMILES
NS(C1=NN(C(S1)=N2)C=C2C3=CC=CC=C3)(=O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AEG 3482 Research References

  1. [1] Nguyen L, Thewes L, Westerhoff M, et al. JNK Signalling Regulates Self-Renewal of Proliferative Urine-Derived Renal Progenitor Cells via Inhibition of Ferroptosis. Cells (2023). PMID: 37681928 DOI: 10.3390/cells12172197 Source material
  2. [2] Ryals M, Morell RJ, Martin D, et al. The Inner Ear Heat Shock Transcriptional Signature Identifies Compounds That Protect Against Aminoglycoside Ototoxicity. Front Cell Neurosci (2018). PMID: 30532693 DOI: 10.3389/fncel.2018.00445 Source material
  3. [3] Lombard DB, Kohler WJ, Guo AH, et al. High-throughput small molecule screening reveals Nrf2-dependent and -independent pathways of cellular stress resistance. Sci Adv (2020). PMID: 33008901 DOI: 10.1126/sciadv.aaz7628 Source material

Added to your cart

View Cart Checkout
Loading...